Regen BioPharma Reports Fiscal Year 2025 Financial Results with Increased Net Loss

Regen BioPharma, Inc. reported its financial results for the fiscal year ending September 30, 2025, revealing total revenues of $236,561, a marginal increase from $236,560 in the previous year. The revenue breakdown included $126,560 from licensing agreements with Oncology Pharma, Inc. and $110,001 from related party transactions with Zander Therapeutics, Inc. Despite the stable revenue figures, the company experienced a net loss of $1,274,502, significantly higher than the $668,255 loss reported for the fiscal year 2024. This increase in net loss was primarily attributed to a substantial derivative expense of $675,528 recognized during the year.

Operating expenses for the year decreased to $575,101 from $653,781 in the prior year, driven by a notable reduction in research and development costs, which fell from $153,685 to $11,725. However, general and administrative expenses rose to $75,113 from $58,920, and consulting and professional fees increased to $398,263 from $363,961. The overall decrease in operating expenses was not sufficient to offset the increase in other expenses, leading to a loss from operations of $338,540, an improvement from the previous year's loss of $417,221.

In terms of strategic developments, Regen BioPharma entered into consulting agreements with Dr. Harry Lander and its CEO David Koos, each receiving 20 million shares as compensation for their roles in a planned Phase I clinical trial of HemaXellerate. The company also issued a total of 1,780,000 common shares for $17,800 and 5,000,000 shares to satisfy convertible debt obligations. As of September 30, 2025, the company had approximately 481 holders of common stock and 480 holders of Series A preferred stock, reflecting a stable shareholder base.

Operationally, Regen BioPharma reported a net cash used in operating activities of $383,591, a decrease from $751,536 in the previous year, indicating improved cash management. The company generated $452,430 from financing activities, primarily through the issuance of common stock and convertible notes. As of the end of the fiscal year, the company had cash reserves of $69,555 and a working capital deficit of approximately $6.2 million, raising concerns about its ability to continue as a going concern without additional funding.

Looking ahead, Regen BioPharma's management expressed the need for significant capital to support ongoing operations and product development. The company plans to secure additional funding through equity or debt offerings, but there is no guarantee of success. The financial statements indicate that the company has incurred substantial operating losses and negative cash flows since inception, underscoring the challenges it faces in executing its business strategy and achieving profitability in the future.